单唾液酸四己糖神经节苷脂钠联合鼠神经生长因子治疗Bell面瘫的回顾性研究

GM1 combined with NGF for the treatment of Bell's palsy: a retrospective study

目的:探讨单唾液酸四己糖神经节苷脂钠(monosialotetrahexosylganglioside,GM1)联合鼠神经生长因子(nerve growth factor,NGF)在早期治疗Bell面瘫的临床疗效和短期预后。方法 :回顾比较分析2009年1月—2015年9月219例Bell面瘫病例,其中GM1联合NGF组58例,GM1组55例,NGF组51例,未用特殊营养神经药物的基础组55例。所有病例基础治疗相同。通过比较治疗前及治疗后1、2、4周House-Brackmann分级、Sunny Brook综合评分,评价面神经功能的恢复程度。结果:GM1联合NGF组在治疗后2、4周的House-Brackmann分级及Sunny Brook评分均明显优于其他组,差异有统计学意义(P<0.01)。GM1联合NGF组在治疗后4周的痊愈率(91.4%)明显高于GM1组(74.5%)、NGF组(78.4%)及基础组(50.9%),差异有统计学意义(P<0.01)。结论:GM1联合NGF早期治疗Bell面瘫,在面神经功能的早期恢复和改善短期预后方面具有优势。

Objective： To evaluate the efficacy of treatment with monosialotetrahexosyl ganglioside （GM1） combined with mouse nerve growth factor （NGF） on early stage of treatment and short-term prognosis of acute Bell＇ s palsy. Methods： A retrospective study was conducted to analyze clinical data of 219 patients with Bell＇s palsy from January 2009 to December 2015. The patients with a- cute Bell＇s palsy were divided into four groups, including the GM1 combined with NGF group （58 cases）, the GM1 group （55 cases）, the NGF group（51 cases）, and the basic group（without any special neurotrophic drugs, 55 cases）. All cases had the same basic treat- ment. We used the House-Brackmann facial nerve grading system （HB） and the Sunnybrook grading system to evaluate the efficacy of treatment before starting treatment, after 1 week and 2 weeks of treatment and 1 month after onset. Results： There was greater im- provement in the mean HB and Sunnybrook scores of the GM1 combined with NGF group in comparison to the other three groups at 2 weeks and 4 weeks （P〈0.01）. After 4 weeks, 91.4% patients had good recovery in the GM1 combined with NGF group compared with the other three groups （P〈0.01）, the recovery rates of the GM1 group, NGF group and basic group at the same time point were 74.5%, 78.4% and 50.9%, respectively. Conclusion： The combination of GMI and NGF treatment increases the possibility of recovery in a- cute Bell＇s palsy.